imatinib mesylate has been researched along with Lymphocytopenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busque, L; Guimond, M; Laflamme, P; Leboeuf, DM; Moutuou, MM; Roy, J; Sidi Boumedine, R; Thiant, S | 1 |
| Kovacsovics, T; Meylan, P; Senn, L; Tarr, PE | 1 |
| Geh, I; Gregg, RJ; Pallalau, A; Salmons, N; Tanière, P; Woolhouse, I | 1 |
3 other study(ies) available for imatinib mesylate and Lymphocytopenia
| Article | Year |
|---|---|
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Line, Tumor; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphopenia; Mice; Phosphorylation; Receptors, Antigen, T-Cell; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Peritoneal tuberculosis after imatinib therapy.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphopenia; Male; Opportunistic Infections; Peritonitis; Peritonitis, Tuberculous; Piperazines; Pyrimidines | 2009 |
Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Lymphomatoid Granulomatosis; Lymphopenia; Male; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2007 |